Exane Derivatives’s Hudson Pacific Properties HPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$134 Hold
1
﹤0.01% 705
2022
Q1
$250 Hold
1
﹤0.01% 939
2021
Q4
$222 Hold
1
﹤0.01% 835
2021
Q3
$236 Hold
1
﹤0.01% 1002
2021
Q2
$249 Hold
1
﹤0.01% 1005
2021
Q1
$244 Hold
1
﹤0.01% 851
2020
Q4
$216 Hold
1
﹤0.01% 792
2020
Q3
$197 Hold
1
﹤0.01% 722
2020
Q2
$226 Hold
1
﹤0.01% 650
2020
Q1
$228 Hold
1
﹤0.01% 654
2019
Q4
$327 Hold
1
﹤0.01% 637
2019
Q3
$301 Hold
1
﹤0.01% 613
2019
Q2
$299 Sell
1
-24
-96% -$5.76K ﹤0.01% 619
2019
Q1
$5.99K Hold
25
﹤0.01% 411
2018
Q4
$5.05K Hold
25
﹤0.01% 495
2018
Q3
$5.57K Sell
25
-1,139
-98% -$268K ﹤0.01% 460
2018
Q2
$289K Buy
1,164
+1,162
+58,100% +$274K 0.05% 220
2018
Q1
$519 Sell
2
-1,770
-100% -$394K ﹤0.01% 503
2017
Q4
$425K Buy
+1,772
New +$426K 0.07% 186
2017
Q3
Sell
-4
Closed -$923 610
2017
Q2
$923 Sell
4
-2,846
-100% -$683K ﹤0.01% 481
2017
Q1
$691K Buy
+2,850
New +$702K 0.16% 112

Other funds holding HPP

Exane Derivatives's HPP Position: Q2 2022 in Review

Exane Derivatives held its Hudson Pacific Properties (HPP) position steady in Q2 2022 at 1 share worth $134. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Exane Derivatives first reported a position in HPP in Q1 2017 and has held it in 21 quarters since. The position peaked at $691K in Q1 2017. 276 funds tracked by Wall St. Rank hold HPP as of Q2 2022.

  • Exane Derivatives held 1 share of Hudson Pacific Properties worth $134 as of Q2 2022.
  • Exane Derivatives left its Hudson Pacific Properties share count unchanged in Q2 2022.
  • Hudson Pacific Properties made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #705 holding.
  • Exane Derivatives first reported a position in Hudson Pacific Properties in Q1 2017 and has held it in 21 quarters since.
  • Exane Derivatives's Hudson Pacific Properties position peaked at $691K in Q1 2017.
  • 276 funds tracked by Wall St. Rank held Hudson Pacific Properties as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.